MHT治疗绝经综合征的现况概括
Current Status of MHT Treatment for Menopausal Syndrome
DOI: 10.12677/ACM.2023.134764, PDF,   
作者: 范莹莹:青海大学临床医学院妇产科学,青海 西宁;任玉环*:青海大学附属医院妇科,青海 西宁
关键词: MHT绝经综合征现况MHT Menopause Syndrome Present Situation
摘要: 目的:探讨如何更好地运用绝经激素治疗(Menopausal hormone therapy, MHT)治疗绝经综合征。方法:广泛查阅近5年文献,汇总了目前国内外对绝经综合征及MHT的认识。结果:MHT有雌激素,孕激素,复方雌激素 + 孕激素,给药途径包括口服及透皮途径给药等多种方式,应针对患者症状选择个体治疗。结论:MHT对绝经期女性利远远大于弊,但大对数女性对MHT认识不足,过于恐惧其风险而对于其益处却熟视无睹,这显然需要医生及医学生做出更大努力来指导广大妇女了解更年期的病理生理及激素治疗的作用,希望在与健康生活方式的协同作用下,MHT可以改善女性更年期的症状和体征,促进健康长寿。
Abstract: Objective: To explore how to better use postmenopausal hormone therapy (Menopausal-hormonetherapy, MHT) treatment of menopausal syndrome. Methods: The literature of the past 5 years was reviewed extensively, and the understanding of menopausal syndrome and MHT at home and abroad was summarized. Results: MHT has estrogen, progesterone and compound estrogen + progesterone. The administration routes include oral administration and transdermal administra-tion. Individual treatment should be selected according to patients’ symptoms. Conclusion: The ad-vantages of MHT in menopausal women far outweigh the disadvantages, but most women do not know enough about MHT. They are too afraid of its risks and turn a blind eye to its benefits. It is ob-viously necessary for doctors and medical students to make greater efforts to guide women to un-derstand the pathophysiology of menopause and the role of hormone therapy. MHT can improve the symptoms and signs of female menopause and promote healthy longevity.
文章引用:范莹莹, 任玉环. MHT治疗绝经综合征的现况概括[J]. 临床医学进展, 2023, 13(4): 5396-5400. https://doi.org/10.12677/ACM.2023.134764

参考文献

[1] Ali Farid, A., El Bambi, M., El Dali, O., et al. (1996) The Menopause Rating Scale (MRS1Ⅱ)-Clusters of Menopausal Symptoms. Maturitas, 27-201.
[2] 赵迪. 积极心理学视角下农村中年女性绝经前期、围绝经期和绝经后期绝经综合征的对比研究[D]: [硕士学位论文]. 济南: 山东大学, 2019.
[3] 周彦吟. 新加坡华人妇女绝经综合征中医证型研究[D]: [博士学位论文]. 广州: 广州中医药大学, 2021.[CrossRef
[4] 吴卓, 吴佳聪, 万春花. 2000例围绝经期妇女绝经综合征及相关因素分析[J]. 河南预防医学杂志, 2016, 27(7): 485-487+538. [Google Scholar] [CrossRef
[5] 奚鑫, 冉海龙, 陈诚, 杜倩, 李文军, 徐驰宇, 曾婷婷, 李阳美, 雷迅, 范尧, 刘松青, 俞丽丽. 围绝经期一日门诊多学科健康宣教模式对女性绝经激素治疗认知的影响[J]. 中国药房, 2022, 33(5): 628-634.
[6] Lobo, R.A. (2017) Hormone-Replacement Therapy: Current Thinking. Nature Reviews Endocrinology, 13, 220-231. [Google Scholar] [CrossRef] [PubMed]
[7] Burger, H.G., MacLennan, A.H., Huang, K.-E. and Castelo-Branco, C. (2012) Evidence-Based Assessment of the Impact of the WHI on Women’s Health. Climacteric, 15, 281-287. [Google Scholar] [CrossRef] [PubMed]
[8] Baber, R.J., Panay, N. and Fenton, A. (2016) 2016 IMSRecommendations on Women’s Midlife Health and Menopause Hormone Therapy. Climacteric, 19, 109-150. [Google Scholar] [CrossRef] [PubMed]
[9] Gambacciani, M., Biglia, N., Cagnacci, A., et al. (2018) Menopause and Hormone Replacement Therapy: The 2017 Recommendations of the Italian Menopause Society. Minerva Ginecologica, 70, 27-34.
[10] Palacios, S., Stevenson, J.C., Schaudig, K., Lukasiewicz, M. and Graziottin, A. (2019) Hormone Therapy for First-Line Management of Menopausal Symptoms: Practical Recommendations. Women’s Health, 15, Article ID: 1745506519864009. [Google Scholar] [CrossRef] [PubMed]
[11] Rarick, L. (2007) United States Regulatory Considerations for In-trauterine Progestins for Hormone Replacement Therapy. Contraception, 75, S140-S143. [Google Scholar] [CrossRef] [PubMed]
[12] de Villiers, T.J., Pines, A., Panay, N., Gambacciani, M., Archer, D.F., Baber, R.J., Davis, S.R., Gompel, A.A., Henderson, V.W., Langer, R., Lobo, R.A., Plu-Bureau, G. and Sturdee, D.W. (2013) Updated 2013 International Menopause Society Recommendations on Menopausal Hormone Therapy and Preventive Strategies for Midlife Health. Climacteric, 16, 316-337. [Google Scholar] [CrossRef] [PubMed]
[13] Stute, P., Neulen, J. and Wildt, L. (2016) The Impact of Mi-cronized Progesterone on the Endometrium: A Systematic Review. Climacteric, 19, 316-328. [Google Scholar] [CrossRef] [PubMed]
[14] The North American Menopause Society (2017) The 2017 Hormone Therapy Position Statement of the North American Menopause Society. Menopause, 24, 728-753. [Google Scholar] [CrossRef
[15] Christ, J.P., Gunning, M.N., Palla, G., et al. (2018) Estro-gen Deprivation and Cardiovascular Disease Risk in Primary Ovarian Insufficiency. Fertility and Sterility, 109, 594-600. [Google Scholar] [CrossRef] [PubMed]
[16] Gupte, A.A., Pownall, H.J. and Hamilton, D.J. (2015) Estro-gen: An Emerging Regulator of Insulin Action and Mitochondrial Function. Journal of Diabetes Research, 2015, Article ID: 916585. [Google Scholar] [CrossRef] [PubMed]
[17] Renoux, C., Dell’Aniello, S., Garbe, E. and Suissa, S. (2010) Transdermal and Oral Hormone Replacement Therapy and the Risk of Stroke: A Nested Case-Control Study. BMJ, 340, Article No. c2519. [Google Scholar] [CrossRef] [PubMed]
[18] Løkkegaard, E., Nielsen, L.H. and Keiding, N. (2017) Risk of Stroke with Various Types of Menopausal Hormone Therapies: A National Cohort Study. Stroke, 48, 2266-2269. [Google Scholar] [CrossRef
[19] Anderson, G.L., Chlebowski, R.T., Rossouw, J.E., et al. (2006) Prior Hormone Therapy and Breast Cancer Risk in the Women's Health Initiative Randomized Trial of Estrogen Plus Progestin. Maturitas, 55, 103-115. [Google Scholar] [CrossRef] [PubMed]
[20] 郁琦, 崔小娟. 绝经激素治疗临床应用争议及展望[J]. 中国计划生育和妇产科, 2022, 14(1): 3-6+28.